Healthcare Industry News: Cook
News Release - June 9, 2006
Emerging Urological Technologies Addressed at Cook VISTA(TM)Future of Ureteral Stents and Their Applications Discussed by Leading Urologists from Around the World
SPENCER, Ind.--(HSMN NewsFeed)--June 9, 2006--Cook Urological, a member of the Cook Group of companies, the largest privately held medical device manufacturer in the world, hosted the 2006 VISTA Atlanta during the American Urological Association Annual Meeting, May 20-25, 2006. The VISTA featured noted urologists from around the world, speaking on the future of therapeutic ureteral stenting. Used primarily for drainage, ureteral stents will soon be coated with a number of medications much like the paclitaxel-coated stents used in cardiac care. Stents are inserted into a patient's ureters to ensure drainage of fluid from the kidney into the bladder following treatment for kidney stones, compression of the ureter caused by cancer or following a variety of urological procedures.
During his presentation at the Cook VISTA, Dr. John Denstedt, chair of the Department of Surgery at the University of Western Ontario, London Health Sciences Centre, set the stage for the evening's discussion when he told participants, "Stents are plagued with three primary problems that limit their function: encrustation, infection and patient discomfort."
"Drug-eluting biomaterials applied to urology hold considerable promise. The potential to reduce encrustation and limit urinary tract infections would be a significant breakthrough. The discomfort of urinary stents and catheters may be reduced by using drug-eluting biomaterials," Dr. Denstedt added.
Margaret S. Pearle, M.D., Ph.D., Professor of Urology and Internal Medicine at the University of Texas Southwestern Medical Center, served as the moderator of the panel. In addition to Dr. Denstedt other noted physicians that presented at the VISTA and their focus included, Ralph V. Clayman, MD, Chairman of the Department of Urology at the University of California at Irvine, "The Future of Ureteral Stenting for Extrinsic Compression," Evangelos Liatsikos, MD, PhD, of the University of Patras School of Medicine in Greece, "Paclitaxel Stents, Ureteral Applications", and Roberto M. Scarpa, MD, from the University of Torino in Torino Italy "Biofilms and Ureteral Stents".
"Cook has significant expertise in the field of drug elution and we are excited about utilizing our technology to help physicians better serve their patients," said Pete Yonkman, president of Cook Urological Incorporated. "Specifically, Cook is taking a leadership position in guiding the future of ureteral stents to provide significant benefits that extend well beyond typical drainage procedures into therapeutic solutions."
Working with leading urologists, Cook Urological has created a comprehensive line of endourological products that reduce patient trauma by eliminating open surgeries. Cook Urological is recognized worldwide for its innovations in stone management, diagnostic and therapeutic products for the urinary system, and biomaterials for the treatment of urinary incontinence and other forms of urogynecological repairs.
About Cook Urological
Located in Spencer, Indiana, Cook Urological is a member of the Cook family of companies and is the global headquarters for Cook's Urological and Women's Health divisions. Cook® (www.Cookmedical.com) is the world's largest privately held medical device manufacturer and is a leading designer, manufacturer and global distributor of minimally invasive medical device technology for diagnostic and therapeutic procedures. Since its founding in 1963, Cook has created innovative technologies for radiology, cardiology, urology, critical care medicine, general surgery, assisted reproduction, gynecology and obstetrics, endovascular medicine, gastroenterology and endoscopy.
Source: Cook Urological
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.